Conjugated Linoleic Acid Induces an Atheroprotective Macrophage MΦ2 Phenotype and Limits Foam Cell Formation
Overview
Affiliations
Background: Atherosclerosis, the underlying cause of heart attack and strokes, is a progresive dyslipidemic and inflammatory disease where monocyte-derived macrophage cells play a pivotal role. Although most of the mechanisms that contribute to the progression of atherosclerosis have been identified, there is limited information on those governing regression. Conjugated linoleic acid (CLA) is a group of isomers of linoleic acid that differ in the position and/or geometry of their double bonds. We have previously shown that a specific CLA blend (80:20 cis-9,trans-11:trans-10,cis-12-CLA) induces regression of pre-established atherosclerosis in vivo, via modulation of monocyte/macrophage function. However, the exact mechanisms through which CLA mediates this effect remain to be elucidated.
Methods: Here, we address if CLA primes monocytes towards an anti-inflammatory MΦ2 macrophage and examine the effect of individual CLA isomers and the atheroprotective blend on monocyte-macrophage differentiation, cytokine generation, foam cell formation and cholesterol metabolism in human peripheral blood monocyte (HPBMC)-derived macrophages.
Results: cis-9,trans-11-CLA and the atheroprotective 80:20 CLA blend regulates expression of pro-inflammatory mediators and modulates the inflammatory cytokine profile of macrophages and foam cells. In addition, cis-9,trans-11-CLA and CLA blend primes HPBMCs towards an anti-inflammatory MΦ2 phenotype, characterised by increased scavenger receptor (CD36) and efflux protein (ABCA-1) expression. Furthermore, this altered macrophage phenotype impacts on foam cell formation, inhibiting ox-LDL accumulation and promoting cholesterol efflux via both PPARγ and LXRα dependent pathways.
Conclusion: The data increases the understanding of the pathways regulated by CLA in atheroprotection, namely, inhibiting the progressive acquisition of a pro-inflammatory macrophage phenotype.
Saki N, Haybar H, Maniati M, Davari N, Javan M, Moghimian-Boroujeni B J Diabetes Metab Disord. 2024; 23(2):1687-1697.
PMID: 39610485 PMC: 11599683. DOI: 10.1007/s40200-024-01482-8.
Barati F, Bashash D, Mohamadi M, Mehrpori M, Hamidpour M ARYA Atheroscler. 2024; 19(1):25-33.
PMID: 38883152 PMC: 11079296. DOI: 10.48305/arya.2022.11777.2422.
Fitzsimons S, Oggero S, Bruen R, McCarthy C, Strowitzki M, Mahon N Front Immunol. 2021; 11:576516.
PMID: 33391256 PMC: 7773661. DOI: 10.3389/fimmu.2020.576516.
Systematic Review of Multi-Omics Approaches to Investigate Toxicological Effects in Macrophages.
Karkossa I, Raps S, von Bergen M, Schubert K Int J Mol Sci. 2020; 21(24).
PMID: 33317022 PMC: 7764599. DOI: 10.3390/ijms21249371.
miR-155 in the Resolution of Atherosclerosis.
Bruen R, Fitzsimons S, Belton O Front Pharmacol. 2019; 10:463.
PMID: 31139076 PMC: 6527595. DOI: 10.3389/fphar.2019.00463.